What is it about?
This is a supplementary analysis of a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) plus RT vs. 3-weekly cisplatin (100 mg/m2) for postoperative high-risk head and neck cancer.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3-weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.
Perspectives
Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 coucurrent with radition for post operative high-risk head and neck squamous cell carcinoma (HNSCC).
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008, Cancer Medicine, September 2024, Wiley,
DOI: 10.1002/cam4.70235.
You can read the full text:
Contributors
The following have contributed to this page
